Skip to main content

Table 4 Association of pre-transplant panel reactive antibody with primary graft dysfunction status

From: Prevalence of pre-transplant anti-HLA antibodies and their impact on outcomes in lung transplant recipients

 

PGD 0–1 (n = 43)

PGD 2–3 (n = 33)

p-value

Total

   

cPRA

  

> 0.999

 Not detected or PRA < 50%, n (%)

38 (88.4)

29 (87.9)

 

 PRA ≥ 50%, n (%)

5 (11.6)

4 (12.1)

 

Anti-HLA Ab (MFI)

  

0.011

 Not detected or MFI < 3000, n (%)

37 (86.0)

20 (60.6)

 

 MFI ≥ 3000, n (%)

6 (14.0)

13 (39.4)

 

Class I

  

0.394

cPRA

   

 Not detected or PRA < 50%, n (%)

41 (95.3)

29 (87.9)

 

 PRA ≥ 50%, n (%)

2 (4.7)

4 (12.1)

 

Anti-HLA Ab (MFI)

  

0.077

 Not detected or MFI < 3000, n (%)

39 (90.7)

25 (75.8)

 

 MFI ≥ 3000, n (%)

4 (9.3)

8 (24.2)

 

Class II

   

cPRA

   

 Not detected or PRA < 50%, n (%)

40 (93.0)

32 (97.0)

0.628

 PRA ≥ 50%, n (%)

3 (7.0)

1 (3.0)

 

Anti-HLA Ab (MFI)

  

0.071

 Not detected or MFI < 3000, n (%)

41 (95.3)

27 (81.8)

 

 MFI ≥ 3000, n (%)

2 (4.7)

6 (18.2)

 

Donor Specific Antibody

  

0.739

 Yes, n (%)

5 (11.6)

5 (15.2)

 

 No, n (%)

38 (88.4)

28 (84.8)

 
  1. cPRA, calculated panel reactive antibody; PRA, panel reactive antibody; HLA, human leukocyte antigen; MFI, mean fluorescence intensity; PGD, primary graft dysfunction; CMV, cytomegalovirus; R, recipient; D, donor
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us